Ep 5. The Limits of Cancer Treatements, Limits of Computational Modeling, and some words of wisdom.

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/6e/8a/ba/6e8abab4-6815-6b95-7f82-4fdd2a09b50b/mza_16650715835639653740.jpg/600x600bb.jpg

BioTEC Pod

BioTEC

7 episodes

3 days ago

The BioTEC Pod brings you the insights and resources needed to plan impactful careers in biotechnology. Join us as we bring in subject matter experts to discuss and delve into the world of biotechnology.

Science

RSS

All content for BioTEC Pod is the property of BioTEC and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/13463569/13463569-1617206968383-cf03ed4d72741.jpg

Ep 5. The Limits of Cancer Treatements, Limits of Computational Modeling, and some words of wisdom.

BioTEC Pod

43 minutes 19 seconds

4 years ago

Ep 5. The Limits of Cancer Treatements, Limits of Computational Modeling, and some words of wisdom.

On this episode of the BioTEC Pod we are joined by professor Khaled Barakat! Prof.Barakat’s lab is focused on applying computational drug discovery tools to discover new antiviral and immune checkpoints’ small molecule drugs. Prof. Barakat has previously completed his postdoctoral fellowship in the lab of the Nobel Laureate Prof. Michael Houghton. In addition, he serves as the CEO & co-founder of HEKA Therapeutics Inc. and is a co-founder of ACHLYS; two spinoff companies devoted to drug discovery. Learn about the future of cancer treatments, the limits of computational modeling, and spin-off companies with Professor Khaled Barakat. Stay tuned!